HIV Diagnostics Market

Market Overview The Global HIV Diagnostics Market is projected to expand significantly from USD 4.73 billion in 2025 to USD 7.94 billion by 2031, demonstrating a compound annual growth rate of 9.02%. This market encompasses the essential reagents, assays, and instruments used to detect Human Immunodeficiency Virus antibodies, antigens, and viral nucleic acids within biological samples. A key impetus for this growth is the persistent global prevalence of HIV infection, coupled with international funding mandates aimed at achieving universal testing goals, as evidenced by UNAIDS reporting approximately 40.8 million people globally living with HIV in 2024, which necessitates continuous surveillance and frequent screening. Despite these drivers, the market faces a substantial obstacle: the high cost and intricate logistical challenges involved in deploying molecular diagnostics, particularly in resource-limited regions. Inadequate healthcare infrastructure and a shortage of trained laboratory personnel in low-income nations frequently impede the widespread adoption of crucial tools for viral load monitoring and early infant diagnosis. These economic and operational impediments restrict market penetration in areas with a high disease burden, thereby limiting the overall expansion of the global diagnostics industry. Market Driver The expansion of governmental initiatives and public health funding serves as a primary catalyst for the Global HIV Diagnostics Market. International bodies and national health departments are actively intensifying testing programs to achieve eradication targets, leading to substantial procurement volumes for diagnostic supplies. These efforts effectively subsidize the cost of assays in high-burden regions, ensuring a consistent demand for screening services; for instance, The Global Fund reported that its investment partners conducted 46.6 million HIV tests across supported countries in 2024, which contributed to 87% of all people living with HIV globally knowing their status that year, according to UNAIDS data from 2025. Furthermore, the increasing adoption of HIV self-testing kits is significantly driving market growth by decentralizing access and enabling the screening of previously undiagnosed populations. By allowing individuals to conduct tests privately, self-testing technologies overcome barriers related to stigma and limited clinic capacity, particularly benefiting key demographics that are difficult to reach via traditional facilities. This shift towards user-centric diagnostics is strongly supported by major health programs, with the U.S. Department of State indicating that PEPFAR distributed 8.8 million HIV self-test kits during the 2024 fiscal year, showcasing a growing reliance on self-administration to close global diagnostic gaps. Market Challenge The primary challenge impeding the expansion of the Global HIV Diagnostics Market is the prohibitive cost and inherent logistical complexity associated with implementing molecular diagnostics in resource-limited settings. Even though the demand for testing is highest in low-income regions, the significant financial burden of acquiring advanced instruments and the stringent technical requirements for reagent maintenance create a formidable barrier to market entry. This disparity prevents the market from expanding into decentralized community settings, thereby confining revenue generation predominantly to centralized laboratories and ultimately limiting the effective sale and utilization volume of diagnostic kits. Moreover, deficient healthcare infrastructure and a scarcity of trained personnel directly obstruct the widespread adoption of critical testing segments, such as early infant diagnosis. This operational bottleneck leaves a substantial portion of the potential market unserved; for example, UNAIDS reported in 2024 that only 55% of children aged 0–14 years living with HIV had access to treatment, a disparity largely attributable to the inability to implement timely diagnostic testing in high-burden areas. Consequently, these systemic economic and operational constraints collectively cap the industry's growth potential, preventing manufacturers from fully leveraging the global disease burden. Market Trends A critical trend emerging within the Global HIV Diagnostics Market is the increasing adoption of Dual HIV/Syphilis Rapid Diagnostic Tests, driven by the imperative to streamline antenatal care and enhance efficiency in high-burden settings. These multiplex assays enable healthcare providers to screen for both infections simultaneously using a single specimen, substantially reducing the logistical burden and costs associated with separate testing workflows. This integrated approach is particularly vital for preventing mother-to-child transmission, ensuring that pregnant women receive immediate and comprehensive screening during routine visits, and its impact is evident as the Clinton Health Access Initiative reported in October 2025 that strategic implementation enabled syphilis testing coverage to nearly match HIV rates, with three of six monitored countries achieving over 90% coverage for both by 2024. Concurrently, there is a pronounced shift towards Decentralized Point-of-Care Viral Load Monitoring, specifically designed to mitigate the limitations of centralized laboratory networks prevalent in resource-limited geographies. By bringing molecular testing closer to the patient, this trend significantly reduces turnaround times for results, facilitating quicker clinical decision-making and improving adherence to antiretroviral therapy. This transition is essential for bridging gaps in treatment efficacy, given that delayed feedback from distant central laboratories often leads to patient loss to follow-up and the emergence of unmanaged drug resistance; The Global Fund highlighted in its September 2025 'Results Report 2025' that only 74% of people living with HIV in supported countries had a suppressed viral load in 2024, underscoring the substantial market opportunity for point-of-care solutions to boost monitoring frequency and patient suppression rates. Key Market Players * Thermo Fisher Scientific, Inc. * Alere Inc. * Abbott Laboratories inc. * Bristol-Myers Squibb Company * Janssen Global Services, LLC * Gilead Sciences, Inc. * Merck & Co. Inc. * VIIV Healthcare * Beckman Coulter, Inc. * Sysmex Europe SE * Zyomtronix, Inc. * Mylan N.V. * F. Hoffmann-La Roche Ltd. * Siemens Healthcare GmbH Report Scope In this report, the Global HIV Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # HIV Diagnostics Market, By Product * Consumables * Instruments * Software * Services # HIV Diagnostics Market, By Test Type * Antibody Tests(HIV-1 Screening Tests * HIV-1 Antibody Confirmatory Tests * HIV-2 & Group O Diagnostic Tests) * Viral Load Tests * CD4 Test * Others # HIV Diagnostics Market, By Mode * Self-Test * Lab-based # HIV Diagnostics Market, By End-use * Diagnostic Laboratories * Hospitals & Clinics * Home Settings # HIV Diagnostics Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global HIV Diagnostics Market. Available Customizations: Global HIV Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).